Mr Geert Mudde | Founder and Chief Scientific Officer
Tyg Oncology Ltd |

Geert C. Mudde received a Ph.D. in immunology from the University of Utrecht in 1985 and started his international professional career at the Swiss Institute for Asthma and Allergy Research in Davos in 1989. In 1992, he joined the pharmaceutical/biotech industry, where he held several senior management positions at the Novartis Research Institute in Vienna, Austria, at the Parke Davis Research Institute in Fresnes, France, at Ingenium Pharmaceuticals, Martinsried, Germany and at igeneon AG, in Austria. In 2006, while joining Baxter BioScience in Vienna on an interim basis, he co-founded the successful biotech company f-star, where he served as CSO until he started to focus on the development of the S-TIR™ technology platform, for human specific therapeutic vaccines to treat  (severe) allergy and cancer resulting in the foundation of S-TARget therapeutics GmbH in 2010, OncoQR ML GmbH in 2013 and TYG oncology Ltd. in 2013.